Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804660 | 1.00 | LSS (0.39) | LSSHSD11B1ASGR1KAT6AKAT8 | |
| SCHEMBL4802892 | 0.89 | LSS (0.44) | LSSHSD11B1ASGR1 | |
| SCHEMBL4802896 | 0.89 | LSS (0.44) | LSSHSD11B1ASGR1 | |
| SCHEMBL4803216 | 0.87 | LSS (0.48) | LSSHSD11B1ASGR1 | |
| SCHEMBL4803228 | 0.87 | LSS (0.48) | LSSHSD11B1ASGR1 | |
| SCHEMBL4807856 | 0.83 | LSS (0.47) | LSSHSD11B1ASGR1KAT6AKAT8 | |
| SCHEMBL4807851 | 0.83 | LSS (0.47) | LSSHSD11B1ASGR1KAT6AKAT8 | |
| SCHEMBL24136606 | 0.82 | HSD11B1 (0.40) | LSSHSD11B1ASGR1 | |
| SCHEMBL18624578 | 0.82 | HSD11B1 (0.40) | LSSHSD11B1ASGR1 | |
| SCHEMBL5761307 | 0.82 | HSD11B1 (0.36) | LSSHSD11B1ASGR1KAT6AKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311475-B1 | AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | EP | disclosed |
| US-7335687-B2 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1458683-B1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7012077-B2 | Substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | ACKERMANN JEAN (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6858651-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1458683-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-20030186984-A1 | Substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003053933-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| EP-1311475-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2002014267-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186984-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | LSS 2/4885HSD11B1 19/4885ASGR1 1121/4885 |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | LSS 2/4885HSD11B1 14/4885ASGR1 1643/4885 |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | LSS 2/4885HSD11B1 14/4885ASGR1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.